![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)
January 13, 2014 08:00 ET
|
Prosensa Holding N.V.
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present Corporate Overview at the 32nd Annual J.P. Morgan Healthcare Conference
January 07, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced
today that Hans GCP Schikan, Chief Executive Officer, will present
a corporate overview at the...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Comments on Drisapersen Program Update
December 19, 2013 11:06 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel
December 10, 2013 09:15 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, today...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa and Partners Awarded Second European Consortium FP7 Research Grant
November 25, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments
November 18, 2013 08:00 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards
November 15, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, has been...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2013 Financial Results on November 18, 2013
November 11, 2013 08:09 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Monday, November...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy
November 07, 2013 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Host Conference Call to Discuss Recent Drisapersen Data Presentations
October 03, 2013 16:30 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...